Alterity Therapeutics Ltd
ASX:ATH

Watchlist Manager
Alterity Therapeutics Ltd Logo
Alterity Therapeutics Ltd
ASX:ATH
Watchlist
Price: 0.009 AUD Market Closed
Market Cap: 97.9m AUD

Alterity Therapeutics Ltd
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Alterity Therapeutics Ltd
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Alterity Therapeutics Ltd
ASX:ATH
Other Items
-AU$7.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-47%
Opthea Ltd
ASX:OPT
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Other Items
$800k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Other Items
$148m
CAGR 3-Years
N/A
CAGR 5-Years
177%
CAGR 10-Years
77%
Telix Pharmaceuticals Ltd
ASX:TLX
Other Items
-AU$56.2m
CAGR 3-Years
-243%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Alterity Therapeutics Ltd
Glance View

Market Cap
97.9m AUD
Industry
Biotechnology

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. The company is headquartered in Melbourne, Victoria and currently employs 11 full-time employees. The company went IPO on 2000-03-28. The firm focuses on developing disease modifying treatments for neurodegenerative conditions. The firm's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The firm also has a drug discovery platform generating chemical to intercede in disease processes.

ATH Intrinsic Value
0.047 AUD
Undervaluation 81%
Intrinsic Value
Price

See Also

What is Alterity Therapeutics Ltd's Other Items?
Other Items
-7.5m AUD

Based on the financial report for Jun 30, 2025, Alterity Therapeutics Ltd's Other Items amounts to -7.5m AUD.

What is Alterity Therapeutics Ltd's Other Items growth rate?
Other Items CAGR 10Y
-47%

Back to Top